Impact of the 2nd, 3rd and 4th waves of the COVID-19 pandemic on wait times in head and neck cancer: A retrospective study in a French expert center

Autor: Potier, A.-L., Leroy, M., Mortuaire, G., Rysman, B., Morisse, M., Mouawad, F.

Publikováno v: In European Annals of Otorhinolaryngology, Head and Neck diseases September 2024 141(5):268-274

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Erratum to "Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study" [Cancer Radiother. 28 (2024) 373-379].

Autor: Jan L; ENT and Head and Neck Surgery Department, hôpital Huriez, université de Lille, Lille, France., Labreuche J; ULR 2694 Evaluation of Health Technologies and Medical Practices (METRICS), CHU de Lille, université de Lille, 59037 Lille cedex, France., Liem X; Department of Radiation Oncology, centre Oscar-Lambret, Lille, France., Rysman B; ENT and Head and Neck Surgery Department, hôpital Huriez, université de Lille, Lille, France., Morisse M; ENT and Head and Neck Surgery Department, hôpital Huriez, université de Lille, Lille, France., Mortuaire G; ENT and Head and Neck Surgery Department, hôpital Huriez, université de Lille, Lille, France., Mouawad F; ENT and Head and Neck Surgery Department, hôpital Huriez, université de Lille, Lille, France; « Cancer Heterogeneity, Plasticity and Resistance to Therapies » (CANTHER), centre Oscar-Lambret, UMR9020 CNRS, U1277 Inserm, CHU de Lille, université de Lille, 59037 Lille cedex, France. Electronic address: Francois.mouawad@chu-lille.fr.

Publikováno v: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2024 Oct 29. Date of Electronic Publication: 2024 Oct 29.

Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma.

Autor: Morisse M; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Bourhis T; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Lévêque R; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Guilbert M; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Cicero J; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Palma M; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Chevalier D; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., le Bourhis X; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Toillon RA; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Mouawad F; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jul 27; Vol. 13, pp. 661775. Date of Electronic Publication: 2023 Jul 27 (Print Publication: 2023).

RETROSPECTIVE ANALYSIS OF LONG-TERM RESPONSE TO BEVACIZUMAB IN COMBINATION WITH IRINOTECAN FOR RECURRENT GLIOBLASTOMA: IDENTIFICATION OF PROGNOSTIC FACTORS

Autor: Besson, C., Morisse, M., Brut, H., Waissi, W., Noel, G., Chauffert, Bruno, Prebay, D., Schott, R., Etienne-Selloum, N.

Publikováno v: Neuro-Oncology
Neuro-Oncology, 2019, 21 (3), pp.98. ⟨10.1093/neuonc/noz126.360⟩

14th Meeting of the European-Association-of-Neuro-Oncology (EANO), Lyon, FRANCE, SEP 19-22, 2019; International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2755::6315ed9105e8df995023dc7860e7e5a5
https://hal-u-picardie.archives-ouvertes.fr/hal-03598663